S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
OTCMKTS:HLUYY

H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

$22.00
-0.01 (-0.02%)
(As of 08/9/2022)
Today's Range
$22.00
$24.00
50-Day Range
$22.00
$22.00
52-Week Range
$10.00
$31.55
Volume
7,500 shs
Average Volume
1,758 shs
Market Capitalization
$21.91 billion
P/E Ratio
25.00
Dividend Yield
0.91%
Price Target
N/A
HLUYY stock logo

About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

HLUYY Stock Price History

HLUYY Stock News Headlines

H. Lundbeck A/s (OTC: HLUYY)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
H Lundbeck A/S ADR (HLUYY)
H. Lundbeck A/S Cl A
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
H Lundbeck B (0ND5)
H. Lundbeck A/S reports Q1 results
H. Lundbeck A/S reports FY results
H. Lundbeck A/S (HLUN-B.CO)
H Lundbeck B (HLUNb)
See More Headlines
Receive HLUYY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2015
Today
4/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private Households
Sub-Industry
N/A
Current Symbol
OTCMKTS:HLUYY
CIK
N/A
Employees
5,348
Year Founded
1915

Profitability

Net Income
$209.69 million
Pretax Margin
7.83%

Debt

Sales & Book Value

Annual Sales
$2.59 billion
Cash Flow
$3.36 per share
Book Value
$14.60 per share

Miscellaneous

Free Float
N/A
Market Cap
$21.91 billion
Optionable
Not Optionable
Beta
0.68

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Deborah Dunsire M.D. (Age 60)
    Pres & CEO
    Comp: $7.16M
  • Mr. Jacob Tolstrup (Age 50)
    Exec. VP of Commercial Operations & Chief Commercial Officer
    Comp: $888.17k
  • Mr. Lars Bang (Age 60)
    Exec. VP of Product Devel. & Supply
    Comp: $915.5k
  • Dr. Per Johan Luthman (Age 63)
    Exec. VP of R&D
    Comp: $901.84k
  • Mr. Bjorn R. Mogensen
    Sr. VP Group Fin.
  • Dr. Tarek Samad Ph.D.
    Sr. VP & Head of Research
  • Mr. Palle Holm Olesen
    Chief Specialist & VP of Investor Relations
  • Ms. Elise Hauge (Age 55)
    Exec. VP of People & Communication
  • Mr. Ole Chrintz (Age 64)
    Sr. VP of International Markets
  • Mr. Keld Flintholm Jorgensen (Age 51)
    Exec. VP of Corp. Strategy & Bus. Devel.

Should I Buy H. Lundbeck A/S Stock? HLUYY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in H. Lundbeck A/S:

  • H. Lundbeck A/S has a diverse portfolio of pharmaceutical products targeting psychiatric and neurological disorders, providing a wide range of revenue streams.
  • The company's recent partnership agreements and collaborations indicate a focus on innovation and potential for future growth.
  • With the introduction of Vyepti for migraine prevention, H. Lundbeck A/S has expanded its product offerings into a high-demand therapeutic area.
  • Investors may find the company's focus on real-world evidence in support of migraine therapy promising for market differentiation and potential market share growth.
  • Current stock price of HLUYY is showing a positive trend, indicating potential value appreciation for investors.

Cons

Investors should be bearish about investing in H. Lundbeck A/S for these reasons:

  • The competitive landscape in the pharmaceutical industry can pose challenges for market share and pricing pressures.
  • Regulatory uncertainties and changes in healthcare policies could impact the company's product development and market access.
  • Dependency on a few key products for a significant portion of revenue may expose the company to risks associated with product lifecycle and patent expirations.
  • Fluctuations in currency exchange rates can affect the company's financial performance, especially in international markets.
  • Market volatility and macroeconomic factors may influence investor sentiment towards the company's stock.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these H. Lundbeck A/S pros and cons to contact@marketbeat.com.

HLUYY Stock Analysis - Frequently Asked Questions

Should I buy or sell H. Lundbeck A/S stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" HLUYY shares.
View HLUYY analyst ratings
or view top-rated stocks.

How have HLUYY shares performed in 2024?

H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY stock has increased by 0.0% and is now trading at $22.00.
View the best growth stocks for 2024 here
.

How were H. Lundbeck A/S's earnings last quarter?

H. Lundbeck A/S (OTCMKTS:HLUYY) posted its quarterly earnings results on Wednesday, November, 4th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.16. The company had revenue of $547.05 million for the quarter, compared to analyst estimates of $514.82 million. H. Lundbeck A/S had a net margin of 6.74% and a trailing twelve-month return on equity of 13.74%.

Is H. Lundbeck A/S a good dividend stock?

H. Lundbeck A/S (OTCMKTS:HLUYY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.91%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLUYY will have a dividend payout ratio of 7.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HLUYY.

How do I buy shares of H. Lundbeck A/S?

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does H. Lundbeck A/S have any subsidiaries?
The following companies are subsidiares of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.
Read More
This page (OTCMKTS:HLUYY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners